ALS
21 videos · last 6 months shuffled daily, then older videos newest first
▶
6:02 QRL-201 Interim Phase 1/2 Clinical Trial Results
Kasper Roet, CEO and co-founder of QurAlis, presents interim Phase 1/2 results for QRL-201, a therapy designed to restore Stathmin 2, a structural protein lost in ALS.
▶
39:34 HEALEY ALS Platform Trial Webinar: September 24, 2026
Sabrina Paganoni, MD, PhD, and James Berry, MD, MPH, of Mass General Brigham, Michael Weiss, MD, of the University of Washington and Martin Engel, PhD, of Neurizon Therapeutics present updates on the HEALEY ALS Platform Trial and answer audience questions.
▶
43:30 Jeremy Shefner on ALS Research and Clinical Trials
Jeremy Shefner, MD, PhD, of the Barrow Neurological Institute discusses how the success of potential ALS therapies is measured and what successful clinical trials need, on ALS United Mid-Atlantic's GOALS Podcast.
▶
1:32:29 Global Collaboration to Disrupt ALS with Dr. David Taylor
Dr. David Taylor discusses developments shaping ALS research in 2026, including international collaboration, artificial intelligence, increased investment, evolving clinical trials and biomarkers such as neurofilament, for Everything ALS.
▶
36:15 Clene Nanomedicine: Gold Nanocrystals, ALS and the FDA Accelerated Path
Clene Nanomedicine CEO Rob Etherington and Chief Science Officer Mark Mortenson discuss CNM-Au8, the company's gold nanocrystal drug candidate for ALS, its clinical data and its regulatory path with the FDA.
▶
1:37:01 Citizen Research: You Don't Have to Be a Scientist to Think Critically About Research
A session from Everything ALS explains how biomarkers are used in clinical trials, why they matter, how different types of biomarkers serve different purposes, and how they can help researchers better understand treatment effects and improve future trial design.
▶
55:44 Platform Trials in Neurodegeneration: Lessons from ALS
Sabrina Paganoni, MD, PhD, of Harvard Medical School and Mass General Brigham, a Co-Principal Investigator of the HEALEY ALS Platform Trial, presents lessons from ALS on advancing drug development for neurodegenerative diseases through platform trials.
▶
2:23 Dallas Clinical Trial Tests Experimental Treatment for ALS
NBC 5's Bianca Castro reports on a Dallas trial testing whether a new treatment can slow the progression of ALS.
▶
16:28 NINDS ALS Expanded Access Program: Funding Webinar
NINDS explains funding opportunity RFA-NS-26-001 for its ALS Expanded Access Program, covering requirements, eligibility, how to apply, peer review, cooperative agreement roles and the sharing of biospecimens and data.
▶
11:39 From UNC13A Cryptic Exon Discovery to Clinical Trial
Dr. Aaron Gitler of Stanford on how work from his first Target ALS-funded consortium 13 years ago moved from studying RNA-binding proteins to a therapeutic strategy for ALS.
▶
1:01:27 Be a Champion: Alexion Clinical Trials for ALS
A video by EverythingALS discusses the CHAMPION clinical trial for ALS.
▶
2:28 Possible Breakthrough in ALS Treatment from Israel
A video looks at a new promising therapy for Amyotrophic lateral sclerosis (ALS) using stem cells from Kadimastem, based in Ness Ziona of central Israel.
▶
56:06 Platform Clinical Trials for ALS: A New Paradigm?
A webinar by Mass General Hospital discusses Clinical Trials for ALS, including Platform Trials.
▶
10:42 The Future of Brain Implants and Brain Computer Interfaces Including Use In ALS
The Economist looks at Brain Computer Interfaces that work directly with computers and allow people to control them from the brain including people with diseases like ALS.
▶
57:35 Why Patient Centricity Is No Longer Optional in ALS Clinical Trials
Neuropsychologist Paul Wicks and ALS advocate Cathy Collet discuss why patient involvement in ALS trials matters for recruitment, retention and data quality, in a Sano Genetics webinar.
▶
10:59 Is the US FDA Holding Back Treatments That May Help ALS Patients?
This video looks at patients and their attempts to get Toferson along with other treatments that may be "likely" to help.
▶
3:15 Lumbar Punctures in ALS Clinical Trials
Dr. Shafeeq Ladha, Site Investigator for the HEALEY ALS Platform Trial at Barrow Neurological Institute, gives a step-by-step guide to lumbar punctures as a study procedure in ALS clinical trials.
▶
3:13 Tofersen Approved for Rare Inherited Form of ALS
WashU Medicine reports on the FDA approval of Biogen's tofersen for SOD1 ALS, based in part on Washington University research, and on the stabilisation seen in some phase 3 trial participants.
▶
31:21 Regeneron's ALN-SOD Trial in SOD1-ALS
Oren Levy, MD, Medical Director in the Genetic Medicines Unit of Regeneron Pharmaceuticals, presents the ALN-SOD clinical trial, a study of the safety and tolerability of ALN-SOD in people with SOD1-ALS, in an ALS Canada webinar.
▶
48:44 Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo
Dr. Joseph Palumbo, chief medical officer at BioVie Pharma, on moving from academic research to drug development, and the long road to an FDA-approved ALS treatment.
▶
3:33 Synchron's Stentrode Clinical Trials of Brain Interface
An ALS patient uses Synchron's Stentrode, a brain computer interface, in a feasibility study to control a computer in this video looking at the new technology.